Clinical practice guidelines and treatment decision pathways for multiple therapeutic areas were updated during 2022, including those for diagnosis and management of nonalcoholic fatty liver disease, heart failure management, obesity, and preexposure prophylaxis for HIV prevention.
For time-constrained primary care clinicians, Patient Care® summarizes key additions and other changes to these evidence-based, "living" documents, in a Guideline Topline. These Toplines are at-a-glance slide shows, a convenient format to click through for the high-level kernels that may influence daily practice. (Please note that this collection is not comprehensive but reflects clinical areas frequently addressed in the primary care setting.)
A guideline topline of the CDC's 2022 revised clinical recommendations for prescribing opioids for pain in adults.
The American Gastroenterological Association released its first medical guideline recommending prescription medications for weight loss in adults with obesity. A review, here.
Reduce potential for promoting or worsening hypertension by stopping, reducing, or using alternatives to these 13 drugs and substances.
Obstructive sleep apnea is a cause of secondary hypertension in up to 50% of cases; more common causes here, from the 2017 ACC/AHA hypertension guidelines.
White coat and masked hypertension can be elusive and dangerous. Click through a topline look at recommendations from the 2017 ACC/AHA hypertension guidelines.
An overview of recommendations from the American Association of Clinical Endocrinology for the management of NAFLD in adults.
Get an overview of the recent AACE guidelines for diagnosing NAFLD in adults in primary care settings.
NAFLD is a key risk factor for ASCVD and widely underdiagnosed. This Guideline Topline summarizes new AHA warnings, guidance.
The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.
The CDC update recommends that clinicians advise all sexually active patients about PrEP and includes a new section on prescribing injectable bimonthly cabotegravir.
The American Academy of Neurology recently issued a guideline on oral and topical treatments for painful diabetic neuropathy. Here, a concise summary for clinicians.